Oxidative stress induced thrombosis and Hypercholesterolemic condition in COVID-19 infection

Abstract

The unprecedented emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has put an enormous challenge to the healthcare system worldwide due to the lack of specific treatment options. Several studies found that patients with COVID-19 infection are developing thrombosis. There is a desperate need of understanding the mechanism by which COVID-19 infection is causing the generation of such thrombotic events. In this review, we suggest that excessive production of ROS induces endothelial cell dysfunction which results the release of von Willebrand factor. High von Willebrand factor leads to thrombus production. We also argue that hypercholesterolemia is a life-threatening comorbidity as it can influence thrombus formation by overwhelming production of OxLDL in the presence of COVID-19 infection. Lastly, we present drugs that are suitable in these conditions and their possible drug-drug interaction with investigational antiviral agents used against COVID-19 infection.